Delivery Order SPE2DB22D9143-SPE2DB25FZC05

Award Date 5/19/25
Potential Completion Date 5/20/25
Potential Value $8.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract valued at $8,622.72 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of 120 units of the pharmaceutical product XTANDI 40 MG CAPSULE. This order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA's Medical Supply Chain division, valued at up to $499,999,999. The IDC runs through December 31, 2025...
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $8,622.72, is for the delivery of XTANDI 40 MG CAPSULE 120S to the DLA. This is a firm fixed-price delivery order contract with an ultimate completion date of April 22, 2024. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,622.72 firm fixed-price delivery order is for the supply of XTANDI 40 MG CAPSULE 120S, a specialized pharmaceutical product. The contract has an ultimate completion date of December 17, 2024. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the...
The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, worth up to $4,169.59, is for the delivery of XTANDI 40 MG TABLET 120S, with an ultimate completion date of April 5, 2024. This award is part of a larger indefinite delivery contract, SPE2DB, that DMS Pharmaceutical Group holds with the DLA, valued at...
This federal contract award, valued at $25,868.10, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The award is a delivery order under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of...
The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The $8,622.72 contract is for the delivery of 120 capsules of the pharmaceutical product XTANDI 40 MG. This delivery order was issued under DMS Pharmaceutical Group's larger $499,999,999 indefinite delivery contract (IDC) with the DLA, which runs through December 31, 2025. The IDC...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $4,169.59 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of the prescription drug XTANDI (80 mg tablet, 60-count) and has an ultimate completion date of October 23, 2024. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $12,934.05 Firm Fixed Price delivery order contract is for the provision of XTANDI 40 MG CAPSULE 120S to support the recurring medical supply needs of military health facilities. This award is under DMS Pharmaceutical Group's $499,999,999 indefinite delivery contract (IDC) with the DLA, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a $4,169.59 firm fixed-price delivery order for the pharmaceutical product XTANDI 40 MG TABLET 120S. The contract has an ultimate completion date of January 15, 2025. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $4,321.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, which has an ultimate completion date of August 1, 2022, is for the supply of 4557937756 - XTANDI 40 MG CAPSULE 120S. This award is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 with DMS Pharmaceutical Group, which runs...
  • SPE2DB22D9143
    Indefinite Delivery Contract
  • SPE2DB22D9143-SPE2DB25FZC05
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $8,622.72 firm fixed-price delivery order is for the supply of 120 units of the prescription drug XTANDI 40 MG CAPSULE. The contract has an ultimate completion date of May 20, 2025.

DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC allows the DLA to issue delivery orders for a wide range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide.

Generated 8/18/25, 9:42 AM